Journal of Adolescent Health
Volume 37, Issue 6, Supplement , Pages S10-S16 , December 2005

Vaccination as a prevention strategy for human papillomavirus-related diseases

  • Jessica A. Kahn, M.D., M.P.H.

      Affiliations

    • Corresponding Author InformationAddress correspondence to: Dr. Jessica A. Kahn, Department of Pediatrics, Division of Adolescent Medicine, MLC 4000, Cincinnati Children’s Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229.

Received 19 July 2005 ,Accepted 30 August 2005.

References 

  1. Brown DR , Shew ML , Qadadri B , et al.   A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women . J Infect Dis . 2005;191:182–192
  2. Kahn JA , Hillard PA . Human papillomavirus and cervical cytology in adolescents . Adolesc Med Clin . 2004;15:301–321
  3. Bosch FX , Lorincz A , Munoz N , et al.   The causal relation between human papillomavirus and cervical cancer . J Clin Pathol . 2002;55:244–265
  4. Gillison ML , Lowy DR . A causal role for human papillomavirus in head and neck cancer . Lancet . 2004;363:1488–1489
  5. Castle PE , Schiffman M , Bratti MC , et al.   A population-based study of vaginal human papillomavirus infection in hysterectomized women . J Infect Dis . 2004;190:458–467
  6. Daling JR , Madeleine MM , Johnson LG , et al.   Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer . Cancer . 2004;101:270–280
  7. Beutner KR , Reitano MV , Richwald GA , et al.  AMA Expert Panel on External Genital Warts   External genital warts (report of the American Medical Association Consensus Conference) . Clin Infect Dis . 1998;27:796–806
  8. Tjiong MY , Out TA , Ter Schegget J , et al.   Epidemiologic and mucosal immunologic aspects of HPV infection and HPV-related cervical carcinoma in the lower female genital tract (a review) . Int J Gynecol Cancer . 2001;11:9–17
  9. Munoz N , Bosch FX , de Sanjose S , et al.   Epidemiologic classification of human papillomavirus types associated with cervical cancer . N Engl J Med . 2003;348:518–527
  10. Bergler WF , Gotte K . Current advances in the basic research and clinical management of juvenile-onset recurrent respiratory papillomatosis . Eur Arch Otorhinolaryngol . 2000;257:263–269
  11. von Krogh G , Lacey CJ , Gross G , et al.   European guideline for the management of anogenital warts . Int J STD AIDS . 2001;12(suppl 3):40–47
  12. Silverberg MJ , Thorsen P , Lindeberg H , et al.   Condyloma in pregnancy is strongly predictive of juvenile-onset recurrent respiratory papillomatosis . Obstet Gynecol . 2003;101:645–652
  13. Beutner KR , Becker TM , Stone KM . Epidemiology of human papillomavirus infections . Dermatol Clin . 1991;9:211–218
  14. Koutsky LA , Galloway DA , Holmes KK . Epidemiology of genital human papillomavirus infection . Epidemiol Rev . 1988;10:122–163
  15. Law CL , Merianos A , Grace J , et al.   Clinical and virological associations between external anogenital warts and cervical HPV infection in an STD clinic population . Int J STD AIDS . 1991;2:30–36
  16. Horn JE , McQuillan GM , Shah KV , et al.   Genital human papillomavirus infections in patients attending an inner-city STD clinic . Sex Transm Dis . 1991;18:183–187
  17. Cook LS , Koutsky LA , Holmes KK . Clinical presentation of genital warts among circumcised and uncircumcised heterosexual men attending an urban STD clinic . Genitourin Med . 1993;69:262–264
  18. Persson G , Dahlof LG , Krantz I . Physical and psychological effects of anogenital warts on female patients . Sex Transm Dis . 1993;20:10–13
  19. Chandler MG . Genital warts (a study of patient anxiety and information needs) . Br J Nurs . 1996;5:174–179
  20. Insinga RP , Glass AG , Rush BB . The health care costs of cervical human papillomavirus-related disease . Am J Obstet Gynecol . 2004;191:114–120
  21. Insinga RP , Dasbach EJ , Myers ER . The health and economic burden of genital warts in a set of private health plans in the United States . Clin Infect Dis . 2003;36:1397–1403
  22. Lowy DR , Frazer IH . Chapter 16 (prophylactic human papillomavirus vaccines) . J Natl Cancer Inst Monogr . 2003;111–116
  23. Schiller JT , Davies P . Delivering on the promise (HPV vaccines and cervical cancer) . Nat Rev Microbiol . 2004;2:343–347
  24. Christensen ND . Emerging human papillomavirus vaccines . Expert Opin Emerg Drugs . 2005;10:5–19
  25. Gravitt PE , Shah KV . A virus-based vaccine may prevent cervical cancer . Curr Infect Dis Rep . 2005;7:125–131
  26. Hagensee ME , Yaegashi N , Galloway DA . Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins . J Virol . 1993;67:315–322
  27. Kirnbauer R , Taub J , Greenstone H , et al.   Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles . J Virol . 1993;67:6929–6936
  28. Fife KH , Wheeler CM , Koutsky LA , et al.   Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women . Vaccine . 2004;22:2943–2952
  29. Ault KA , Giuliano AR , Edwards RP , et al.   A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine . Vaccine . 2004;22:3004–3007
  30. Koutsky LA , Ault KA , Wheeler CM , et al.   A controlled trial of a human papillomavirus type 16 vaccine . N Engl J Med . 2002;347:1645–1651
  31. Harper DM , Franco EL , Wheeler C , et al.   Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women (a randomised controlled trial) . Lancet . 2004;364:1757–1765
  32. Villa LL , Costa RLR , Petta CA , et al.   Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L2 virus-like particle vaccine in young women (a randomised double-blind placebo-controlled multicentre phase II efficacy trial) . Lancet Oncol . 2005;6:271–278 [published online April 7, 2005:D01 10.1016/S470-2045(05)70101–7]
  33. Reinis M . Technology evaluation (HPV vaccine (quadrivalent), Aventis Pasteur MSD/CSL) . Curr Opin Mol Ther . 2004;6:206–211
  34. Skjeldestad FE, et al. Prophylactic quadrivalent human papillomavirus (HPV) (types 6, 11, 16, 18) L1 virus-like particle (VLP) vaccine (Gardasil™) reduces cervical intraepithelial neoplasia (CIN) 2/3 risk. Presented at: Infectious Disease Society of America 43rd Annual Meeting; October 7, 2005; San Francisco, Calif. Abstract LB-8a. Available at: http://www.idsociety.org/Template.cfm?Section=Program2&CONTENTID=14108&TEMPLATE=/ContentManagement/ContentDisplay.cfm. Accessed November 8, 2005.
  35. Hinman AR , Orenstein WA , Mortimer EA . When, where, and how do immunizations fail? . Ann Epidemiol . 1992;2:805–812
  36. Zimet GD , Mays RM , Fortenberry JD . Vaccines against sexually transmitted infections (promise and problems of the magic bullets for prevention and control) . Sex Transm Dis . 2000;27:49–52
  37. Hagensee ME , Cameron JE , Leigh JE , et al.   Human papillomavirus infection and disease in HIV-infected individuals . Am J Med Sci . 2004;328:57–63
  38. Clifford GM , Smith JS , Plummer M , et al.   Human papillomavirus types in invasive cervical cancer worldwide (a meta-analysis) . Br J Cancer . 2003;88:63–73
  39. Munoz N , Bosch FX , Castellsague X , et al.   Against which human papillomavirus types shall we vaccinate and screen? The international perspective . Int J Cancer . 2004;111:278–285
  40. Garnett GP . Role of herd immunity in determining the effect of vaccines against sexually transmitted disease . J Infect Dis . 2005;191(suppl 1):S97–S106
  41. Goldie SJ , Kohli M , Grima D , et al.   Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine . J Natl Cancer Inst . 2004;96:604–615
  42. Mays RM , Sturm LA , Zimet GD . Parental perspectives on vaccinating children against sexually transmitted infections . Soc Sci Med . 2004;58:1405–1413
  43. Zimet GD , Perkins SM , Sturm LA , et al.   Predictors of STI vaccine acceptability among parents and their adolescent children . J Adolesc Health . 2005;37:179–186
  44. Olshen E , Woods ER , Austin SB , et al.   Parental acceptance of the human papillomavirus vaccine . J Adolesc Health . 2005;37:248–251

PII: S1054-139X(05)00407-6

doi: 10.1016/j.jadohealth.2005.08.018

Journal of Adolescent Health
Volume 37, Issue 6, Supplement , Pages S10-S16 , December 2005

Article Tools

* Image Usage & Resolution